|
Jul 2
|
Exploring Three High Growth Tech Stocks In Australia
|
|
Jun 29
|
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data
|
|
Jun 26
|
ASX Penny Stocks Spotlight: Arafura Rare Earths And Two More To Consider
|
|
Jun 23
|
High Growth Tech Stocks In Australia For June 2025
|
|
Jun 23
|
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
|
|
Jun 19
|
Exploring Life360 And 2 Prominent High Growth Tech Stocks In Australia
|
|
May 27
|
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
|
|
Mar 10
|
Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Oct 10
|
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 4
|
Immutep concludes participant enrolment in Phase II breast cancer trial
|
|
Oct 3
|
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
|
|
Sep 24
|
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
|
|
Aug 14
|
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
|
|
Jul 31
|
Immutep Quarterly Activities Report Q4 FY24
|
|
Jun 25
|
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
|
|
May 15
|
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
|
|
May 2
|
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
|
|
Apr 29
|
Immutep Quarterly Activities Report Q3 FY24
|
|
Apr 24
|
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
|
|
Apr 24
|
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
|